Frankfurt - Delayed Quote EUR

Glycorex Transplantation AB (publ) (O33.F)

0.1785
0.0000
(0.00%)
As of 8:09:34 AM GMT+2. Market Open.
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
35,159
35,159
29,962
36,116
28,202
Cost of Revenue
6,935
6,935
3,108
4,572
3,264
Gross Profit
28,224
28,224
26,854
31,544
24,938
Operating Expense
38,666
38,666
44,740
39,956
36,753
Operating Income
-10,442
-10,442
-17,886
-8,412
-11,815
Net Non Operating Interest Income Expense
-560
-560
-89
-224
-269
Pretax Income
-11,002
-11,002
-30,364
-8,520
-12,241
Tax Provision
-61
-61
0
56
2
Net Income Common Stockholders
-10,941
-10,941
-30,364
-8,576
-12,243
Diluted NI Available to Com Stockholders
-10,941
-10,941
-30,364
-8,576
-12,243
Basic EPS
-0.34
-0.15
-0.41
-0.12
-0.17
Diluted EPS
-0.34
-0.15
-0.41
-0.12
-0.17
Basic Average Shares
73,853.9830
73,853.9830
73,853.9830
73,853.9830
73,853.9830
Diluted Average Shares
73,853.9830
73,853.9830
73,853.9830
73,853.9830
73,853.9830
Total Operating Income as Reported
-10,442
-10,442
-30,275
-8,309
-11,844
Total Expenses
45,601
45,601
47,848
44,528
40,017
Net Income from Continuing & Discontinued Operation
-10,941
-10,941
-30,364
-8,576
-12,243
Normalized Income
-10,941
-10,941
-17,975
-8,618.8760
-12,243
Interest Income
--
--
292
23
0
Interest Expense
--
--
289
247
269
Net Interest Income
-560
-560
-89
-224
-269
EBIT
-10,442
-10,442
-17,886
-8,273
-11,972
EBITDA
-1,121
-1,121
-8,939
284
-3,477
Reconciled Cost of Revenue
6,935
6,935
3,108
4,572
3,264
Reconciled Depreciation
9,321
9,321
8,947
8,557
8,495
Net Income from Continuing Operation Net Minority Interest
-10,941
-10,941
-30,364
-8,576
-12,243
Total Unusual Items Excluding Goodwill
--
--
-12,389
54
--
Total Unusual Items
--
--
-12,389
54
--
Normalized EBITDA
-1,121
-1,121
3,450
230
-3,477
Tax Rate for Calcs
0
0
0
0.0002
0.0002
Tax Effect of Unusual Items
0
0
0
11.1240
0
12/31/2021 - 8/30/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PFND Pathfinder Cell Therapy, Inc.
0.0001
0.00%
 
TNGNQ Tengion, Inc.
0.0000
0.00%
 
PZRXQ PhaseRx, Inc.
0.0002
0.00%
 
XENO Xeno Transplants Corporation
0.0001
0.00%
 
PROT Proteonomix, Inc.
0.0000
0.00%
 
DYN Dyne Therapeutics, Inc.
12.05
+2.47%
 
GMAB Genmab A/S
21.05
+2.56%
 
INCY Incyte Corporation
64.81
+0.05%
 
HUMA Humacyte, Inc.
2.4180
+3.33%
 
SEPN Septerna, Inc.
9.56
+5.52%